Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT03654326




Registration number
NCT03654326
Ethics application status
Date submitted
17/08/2018
Date registered
31/08/2018
Date last updated
4/11/2024

Titles & IDs
Public title
A Study to Evaluate the Efficacy and Safety of Gefapixant (MK-7264) in Women With Endometriosis-Related Pain (MK-7264-034)
Scientific title
A Phase 2a, Proof of Concept, Randomized, Double-Blind, Placebo-Controlled Clinical Trial, to Evaluate the Efficacy and Safety of MK-7264 in Women With Moderate to Severe Endometriosis-Related Pain
Secondary ID [1] 0 0
MK-7264-034
Secondary ID [2] 0 0
7264-034
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Endometriosis-related Pain 0 0
Condition category
Condition code
Reproductive Health and Childbirth 0 0 0 0
Other reproductive health and childbirth disorders
Reproductive Health and Childbirth 0 0 0 0
Menstruation and menopause

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Gefapixant
Treatment: Drugs - Placebo
Treatment: Drugs - Naproxen

Experimental: Gefapixant - Participants will receive a gefapixant 45 mg tablet twice a day for approximately 8 weeks (2 menstrual cycles). Naproxen sodium 275 mg tablets will also be provided to participants for use as rescue medication for endometriosis-related pain.

Placebo comparator: Placebo - Participants will receive a placebo matching gefapixant tablet twice a day for approximately 8 weeks (2 menstrual cycles). Naproxen sodium 275 mg tablets will also be provided to participants for use as rescue medication for endometriosis-related pain.


Treatment: Drugs: Gefapixant
Gefapixant tablet 45 mg taken orally

Treatment: Drugs: Placebo
Placebo matching gefapixant tablet taken orally

Treatment: Drugs: Naproxen
Naproxen sodium 275 mg tablets taken orally as needed, at dose prescribed by sites' principal investigator
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Change From Baseline in Average Daily Pelvic Pain Score During Treatment Cycle 2
Timepoint [1] 0 0
Baseline and Treatment Cycle 2 (Week 4 to Week 8; each cycle is approximately 28 days)
Primary outcome [2] 0 0
Percentage of Participants Who Experienced an Adverse Event
Timepoint [2] 0 0
Up to approximately 10 weeks
Primary outcome [3] 0 0
Percentage of Participants Who Discontinued Study Drug Due to an Adverse Event
Timepoint [3] 0 0
Up to approximately 8 weeks
Secondary outcome [1] 0 0
Change From Baseline in Average Daily Cyclic Pelvic Pain Score During Treatment Cycle 2
Timepoint [1] 0 0
Baseline and Treatment Cycle 2 (Week 4 to Week 8; each cycle is approximately 28 days)
Secondary outcome [2] 0 0
Change From Baseline in Average Daily Non-Cyclic Pelvic Pain Score During Treatment Cycle 2
Timepoint [2] 0 0
Baseline and Treatment Cycle 2 (Week 4 to Week 8; each cycle is approximately 28 days)

Eligibility
Key inclusion criteria
* has been surgically (laparoscopy or laparotomy) diagnosed with endometriosis.
* has cyclic AND non-cyclic, moderate to severe endometriosis-related pelvic pain (overall pelvic pain score =5 using a 0-10 NRS, with 0 representing no pain and 10 representing extremely severe pain).
* has had spontaneous menstrual cycles before Visit 1.
* has body mass index (BMI) between 18 kg/m^2 to 40 kg/m^2 at Visit 1.
* is not pregnant, not breastfeeding, and agrees to follow the contraceptive guidance.
* must agree to switch from her usual analgesic medication to only that which is permitted in the study.
Minimum age
18 Years
Maximum age
49 Years
Sex
Females
Can healthy volunteers participate?
No
Key exclusion criteria
* history of hysterectomy and/or bilateral oophorectomy.
* has undiagnosed vaginal bleeding.
* has chronic, non-pelvic pain not caused by endometriosis that requires chronic analgesic.
* has a clinically significant gynecologic condition identified in the screening evaluation.
* has a history of anaphylaxis or cutaneous adverse drug reaction (with or without systemic symptoms) to sulfonamide antibiotics or other sulfonamide-containing drugs.
* has a known allergy/sensitivity or contraindication to gefapixant or its excipients.
* has an allergy/sensitivity/intolerance to naproxen sodium (rescue medication) or any contraindication to its use, or has experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs).
* has a history of endometriosis-related pain that was non-responsive to treatment with combined hormonal contraceptives (CHCs), gonadotropin-releasing hormone (GnRH) antagonists, GnRH agonists, progestins, or aromatase inhibitors.
* has a positive urine pregnancy test at any time before randomization.
* has required more than 2 weeks of continuous use of narcotics for treatment of endometriosis-related pain within 6 months of Visit 1.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
11/09/2018
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
30/06/2020
Sample size
Target
Accrual to date
Final
187
Recruitment in Australia
Recruitment state(s)
NSW,SA,WA
Recruitment hospital [1] 0 0
Paratus Clinical Kanwal ( Site 0004) - Kanwal
Recruitment hospital [2] 0 0
Royal Hospital for Women ( Site 0008) - Randwick
Recruitment hospital [3] 0 0
Holdsworth House Medical Practice ( Site 0009) - Sydney
Recruitment hospital [4] 0 0
Royal Adelaide Hospital ( Site 0007) - Adelaide
Recruitment hospital [5] 0 0
Keogh Institute for Medical Research ( Site 0002) - Nedlands
Recruitment postcode(s) [1] 0 0
2259 - Kanwal
Recruitment postcode(s) [2] 0 0
2031 - Randwick
Recruitment postcode(s) [3] 0 0
2010 - Sydney
Recruitment postcode(s) [4] 0 0
5000 - Adelaide
Recruitment postcode(s) [5] 0 0
6009 - Nedlands
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
Arkansas
Country [4] 0 0
United States of America
State/province [4] 0 0
California
Country [5] 0 0
United States of America
State/province [5] 0 0
Connecticut
Country [6] 0 0
United States of America
State/province [6] 0 0
Florida
Country [7] 0 0
United States of America
State/province [7] 0 0
Louisiana
Country [8] 0 0
United States of America
State/province [8] 0 0
Massachusetts
Country [9] 0 0
United States of America
State/province [9] 0 0
North Carolina
Country [10] 0 0
United States of America
State/province [10] 0 0
South Carolina
Country [11] 0 0
United States of America
State/province [11] 0 0
Tennessee
Country [12] 0 0
United States of America
State/province [12] 0 0
Texas
Country [13] 0 0
United States of America
State/province [13] 0 0
Virginia
Country [14] 0 0
United States of America
State/province [14] 0 0
Washington
Country [15] 0 0
Chile
State/province [15] 0 0
Region De Coquimbo
Country [16] 0 0
Chile
State/province [16] 0 0
Region Metropolitana
Country [17] 0 0
Chile
State/province [17] 0 0
Santiago
Country [18] 0 0
New Zealand
State/province [18] 0 0
Auckland
Country [19] 0 0
New Zealand
State/province [19] 0 0
Christchurch
Country [20] 0 0
Poland
State/province [20] 0 0
Bialystok
Country [21] 0 0
Poland
State/province [21] 0 0
Katowice
Country [22] 0 0
Poland
State/province [22] 0 0
Rybnik
Country [23] 0 0
Poland
State/province [23] 0 0
Skorzewo
Country [24] 0 0
Poland
State/province [24] 0 0
Warszawa
Country [25] 0 0
Poland
State/province [25] 0 0
Wroclaw
Country [26] 0 0
Puerto Rico
State/province [26] 0 0
Bayamon
Country [27] 0 0
Puerto Rico
State/province [27] 0 0
Ponce
Country [28] 0 0
Puerto Rico
State/province [28] 0 0
San Juan
Country [29] 0 0
Russian Federation
State/province [29] 0 0
Kazan
Country [30] 0 0
Russian Federation
State/province [30] 0 0
Moscow
Country [31] 0 0
Russian Federation
State/province [31] 0 0
Saint Petersburg
Country [32] 0 0
Russian Federation
State/province [32] 0 0
Smolensk
Country [33] 0 0
Russian Federation
State/province [33] 0 0
St. Petersburg
Country [34] 0 0
Russian Federation
State/province [34] 0 0
Tomsk
Country [35] 0 0
Spain
State/province [35] 0 0
Madrid
Country [36] 0 0
Spain
State/province [36] 0 0
Alicante
Country [37] 0 0
Spain
State/province [37] 0 0
Barcelona
Country [38] 0 0
Ukraine
State/province [38] 0 0
Ivano-Frankivsk
Country [39] 0 0
Ukraine
State/province [39] 0 0
Kyiv
Country [40] 0 0
Ukraine
State/province [40] 0 0
Odessa
Country [41] 0 0
Ukraine
State/province [41] 0 0
Ternopil
Country [42] 0 0
Ukraine
State/province [42] 0 0
Zaporizhzhya

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Merck Sharp & Dohme LLC
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to evaluate the efficacy, safety, and tolerability of gefapixant (MK-7264) in premenopausal female participants with moderate to severe endometriosis-related pain. The primary hypothesis: gefapixant is superior to placebo in reducing the average daily pelvic pain score (cyclic and non-cyclic, combined) during Treatment Cycle 2.
Trial website
https://clinicaltrials.gov/study/NCT03654326
Trial related presentations / publications
Arbelaez F, Joeng HK, Hussain A, Sunga S, Guan Y, Chawla A, Carmona F, Lines C, Mendizabal G. Randomized, controlled, proof-of-concept trial of gefapixant for endometriosis-related pain. Fertil Steril. 2024 Sep 12:S0015-0282(24)02227-1. doi: 10.1016/j.fertnstert.2024.09.013. Online ahead of print.
Public notes

Contacts
Principal investigator
Name 0 0
Medical Director
Address 0 0
Merck Sharp & Dohme LLC
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT03654326